Teclistamab in Relapsed or Refractory Multiple Myeloma. Reply.

Moreau, Philippe; Girgis, Suzette; Goldberg, Jenna D

Moreau, Philippe; Girgis, Suzette; Goldberg, Jenna D.

Affiliation

Moreau P; University Hospital Hôtel-Dieu, Nantes, France philippe.moreau@chu-nantes.fr.
Girgis S; Janssen Research and Development, Spring House, PA.
Goldberg JD; Janssen Research and Development, Raritan, NJ.

N Engl J Med ; 387(18): 1722-1723, 2022 11 03.

Article in En | MEDLINE | ID: mdl-36322861

Subject(s)

Antibodies, Bispecific; Antineoplastic Agents; Multiple Myeloma; Humans; Multiple Myeloma/drug therapy; Neoplasm Recurrence, Local/drug therapy; Antineoplastic Agents/therapeutic use; Antineoplastic Combined Chemotherapy Protocols; Antibodies, Bispecific/therapeutic use

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Database: MEDLINE Main subject: Antibodies, Bispecific / Multiple Myeloma / Antineoplastic Agents Limits: Humans Language: En Journal: N Engl J Med Year: 2022 Type: Article Affiliation country: France

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google